Lexeo Therapeutics Statistics
Total Valuation
LXEO has a market cap or net worth of $607.25 million. The enterprise value is $492.95 million.
Important Dates
The last earnings date was Wednesday, November 5, 2025, before market open.
| Earnings Date | Nov 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
LXEO has 72.99 million shares outstanding. The number of shares has increased by 54.63% in one year.
| Current Share Class | 72.99M |
| Shares Outstanding | 72.99M |
| Shares Change (YoY) | +54.63% |
| Shares Change (QoQ) | +39.95% |
| Owned by Insiders (%) | 0.29% |
| Owned by Institutions (%) | 53.95% |
| Float | 48.18M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.78 |
| P/TBV Ratio | 5.03 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.40, with a Debt / Equity ratio of 0.07.
| Current Ratio | 7.40 |
| Quick Ratio | 7.11 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,081.17 |
Financial Efficiency
Return on equity (ROE) is -80.69% and return on invested capital (ROIC) is -50.86%.
| Return on Equity (ROE) | -80.69% |
| Return on Assets (ROA) | -44.66% |
| Return on Invested Capital (ROIC) | -50.86% |
| Return on Capital Employed (ROCE) | -89.69% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.46M |
| Employee Count | 72 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +1.09% in the last 52 weeks. The beta is 1.78, so LXEO's price volatility has been higher than the market average.
| Beta (5Y) | 1.78 |
| 52-Week Price Change | +1.09% |
| 50-Day Moving Average | 8.53 |
| 200-Day Moving Average | 5.00 |
| Relative Strength Index (RSI) | 43.23 |
| Average Volume (20 Days) | 1,317,510 |
Short Selling Information
The latest short interest is 5.64 million, so 7.72% of the outstanding shares have been sold short.
| Short Interest | 5.64M |
| Short Previous Month | 5.18M |
| Short % of Shares Out | 7.72% |
| Short % of Float | 11.70% |
| Short Ratio (days to cover) | 3.95 |
Income Statement
| Revenue | n/a |
| Gross Profit | -65.95M |
| Operating Income | -113.52M |
| Pretax Income | -104.97M |
| Net Income | -104.97M |
| EBITDA | -112.93M |
| EBIT | -113.52M |
| Earnings Per Share (EPS) | -$2.45 |
Full Income Statement Balance Sheet
The company has $122.76 million in cash and $8.46 million in debt, giving a net cash position of $114.31 million or $1.57 per share.
| Cash & Cash Equivalents | 122.76M |
| Total Debt | 8.46M |
| Net Cash | 114.31M |
| Net Cash Per Share | $1.57 |
| Equity (Book Value) | 120.83M |
| Book Value Per Share | 2.20 |
| Working Capital | 110.52M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$106.81 million and capital expenditures -$397,000, giving a free cash flow of -$107.21 million.
| Operating Cash Flow | -106.81M |
| Capital Expenditures | -397,000 |
| Free Cash Flow | -107.21M |
| FCF Per Share | -$1.47 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LXEO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -54.63% |
| Shareholder Yield | -54.63% |
| Earnings Yield | -17.29% |
| FCF Yield | -17.65% |
Analyst Forecast
The average price target for LXEO is $18.22, which is 118.99% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $18.22 |
| Price Target Difference | 118.99% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |